4-ethylamino-cyclohexanol | 93285-87-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-ethylamino-cyclohexanol
• 英文别名: 4-(Ethylamino)cyclohexanol；4-(ethylamino)cyclohexan-1-ol
• CAS: 93285-87-1
• 化学式: C₈H₁₇NO
• mdl: MFCD11144191
• 分子量: 143.229
• InChiKey: UERWSGAGIMZBJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(2-bromopyridin-4-yl)-4-(naphthalen-2-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one 、 4-ethylamino-cyclohexanol 在 偶氮二甲酸二异丙酯 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration

  摘要：

  In this Letter, we describe the discovery of selective JNK2 and JNK3 inhibitors, such as 10, that routinely exhibit >10-fold selectivity over JNK1 and >1000-fold selectivity over related MAPKs, p38α and ERK2. Substitution of the naphthalene ring affords an isoform selective JNK3 inhibitor, 30, with approximately 10-fold selectivity over both JNK1 and JNK2. A naphthalene ring penetrates deep into the selectivity pocket accounting for the differentiation amongst the kinases. Interestingly, the gatekeeper Met146 sulfide interacts with the naphthalene ring in a sulfur-π stacking interaction. Compound 38 ameliorates neurotoxicity induced by amyloid-β in human cortical neurons. Lastly, we demonstrate how to install propitious in vitro CNS-like properties into these selective inhibitors.

  DOI：

  10.1016/j.bmcl.2010.11.010
• 作为产物：
  描述：

  4-氨基环己醇 、 乙醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以23.6%的产率得到4-ethylamino-cyclohexanol
  参考文献：
  名称：

  [EN] LIPID NANOPARTICLE COMPOSITION
  [FR] COMPOSITIONS DE NANOPARTICULES LIPIDIQUES

  摘要：

  本文提供的是脂质，可以与其他脂质成分（如中性脂质、胆固醇和聚合物结合的脂质）结合使用，形成脂质纳米颗粒，用于传递治疗剂（例如核酸分子）以用于治疗或预防目的，包括疫苗接种。

  公开号：

  WO2021204175A1

文献信息

• 2-AMINOQUINOLINES
  申请人：Kolczewski Sabine

  公开号：US20090227570A1

  公开（公告）日：2009-09-10

  The present invention is concerned with 2-aminoquinoline derivatives of formula I where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, and n are as defined in the specification and claims, their use 5-HT 5A receptor antagonists, their manufacture, and pharmaceutical compositions containing them.

  本发明涉及式I的2-氨基喹啉衍生物，其中R1、R2、R3、R4、R5、R6、A和n如规范和声明中定义，它们用作5-HT5A受体拮抗剂，它们的制造以及含有它们的药物组合物。
• MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE
  申请人：Durand-Reville Thomas

  公开号：US20110021513A1

  公开（公告）日：2011-01-27

  The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.

  本发明涉及IRAK激酶的调节剂，并提供包含这些调节剂的组合物，以及利用这些调节剂治疗由IRAK激酶介导或相关的疾病或病症的方法。
• [EN] PYRAZOLE[1,5a]PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLE[1,5A]PYRIDINE
  申请人：PALAU PHARMA SA

  公开号：WO2010072823A1

  公开（公告）日：2010-07-01

  Pyrazolo[1,5-a]pyridine derivatives of formula I, wherein the meaning for R1, R2 and R3 is as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.

  式I的吡唑并[1,5-a]吡啶衍生物，其中R1、R2和R3的含义如描述中所披露的。这些化合物可用作JAK3激酶抑制剂。
• [EN] POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS<br/>[FR] ANTAGONISTES DE TLR7/8 POLYCYLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES IMMUNES
  申请人：MERCK PATENT GMBH

  公开号：WO2017106607A1

  公开（公告）日：2017-06-22

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as toll-like receptor 7/8 (TLR7/8) antagonists. In Formula (I), Ring A is aryl or heteroaryl; Ring B is aryl or heteroary; and X is C(R4)2, O, NR4, S, S(R4), or S(R4)2.

  本发明涉及式(I)的化合物及其药学上可接受的组合物，作为Toll样受体7/8（TLR7/8）拮抗剂。在式(I)中，环A是芳基或杂芳基；环B是芳基或杂芳基；X是C(R4)2、O、NR4、S、S(R4)或S(R4)2。
• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Florjancic Alan S.

  公开号：US20110015173A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药用可接受的盐，其中R1a、R1b、R1c、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，该组合物对抑制Cdc7等激酶以及治疗癌症等疾病有用。